Pioglitazone and Insulin Resistance in ADT

NCT05098327 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no participant enrolled due to lack of interest.

Conditions

Prostate Cancer
Insulin Resistance
Diabetes Mellitus, Type 2
Androgen Deficiency

Interventions

DRUG: Pioglitazone 30 mg
DRUG: Placebo

Sponsor

State University of New York at Buffalo

Collaborators

[object Object]